Cara Therapeutics reported $-27848000 in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -112.5M 68.38M
Acelrx Pharmaceuticals ACRX:US $ -8.57M 0.86M
Aerie Pharmaceuticals AERI:US $ -32.04M 85.4M
Cara Therapeutics CARA:US $ -27848000 5.61M
Endo International Ordinary Shares ENDP:US $ 226.56M 52.35M
Halozyme Therapeutics HALO:US $ 76.45M 19.11M
Horizon Pharma HZNP:US $ 291.56M 100.61M
JAZZ PHA JAZZ:US $ 267.26M 90.66M
Pacira Pharmaceuticals PCRX:US $ 41.76M 17.12M
Pain Therapeutics PTIE:US $ -17.51M 3.38M
Revance Therapeutics RVNC:US $ -56.84M 0.66M
Supernus Pharmaceuticals SUPN:US $ 23.33M 17.79M
Teva Pharmaceutical Industries TEVA:US $ 1112M 176M
Vanda Pharmaceuticals VNDA:US $ -6.97M 36.11M